$NVCR

NovoCure Ltd

NovoCure is a global oncology company that develops and markets Tumor Treating Fields (TTFields) therapy, delivered through portable medical devices. Its products are Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer and mesothelioma, and Optune Pax for pancreatic cancer. The devices use electric fields delivered through arrays placed on the skin around a tumor, principally alongside standard cancer treatments. NovoCure markets its products in multiple countries and works with certified prescribers, patients, caregivers and payers to provide treatment and support. NovoCure earns money by billing payers a single monthly fee for a month of therapy, typically negotiating discounts from its list price. It generally distributes products directly to patients, while in certain countries it supplies products through hospitals under contractual arrangements. NovoCure also licenses commercialization rights in Greater China to Zai Lab, which markets its products there. The company was incorporated in Jersey, and its daily management and control are located in Switzerland.

AlphAI earnings readThird quarter 2026 · OCT 29Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
2
—
$143K
Puri Michal Nath
0%
See all $NVCR insider activity →
Low

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

NVCR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning NVCR (NovoCure Ltd). Coverage has been balanced: 2 bullish, 0 neutral, and 2 bearish.

Recent NVCR coverage spans financial news and regulation.

In the last 30 days, NVCR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($143K). The most active reporter was Puri Michal Nath, Chief Human Resources Officer, with 1 filing.

What's driving NVCR

AlphAI scores every news story that mentions NVCR with an AI model for sentiment and relevance, and aggregates insider trades from NovoCure Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NVCR

Score

JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer

Novocure (NVCR) announced that JAMA Network Open published results from the PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer. The trial met its primary endpoint, showing improved overall survival. Secondary endpoints also demonstrated significant benefits in pain management and quality of life. TTFields therapy was well-tolerated with no new safety signals. Novocure aims to inform clinicians and patients with these findings.

Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals

InspireMD (NSPR) received FDA approval for its TCAR stent, while Eli Lilly (LLY) and Bayer (BAYRY) secured approvals for obesity and stroke drugs. Johnson & Johnson (JNJ) won FDA approval for a head and neck cancer treatment. Meanwhile, Sionna (SION), Nano-X (NNOX), and Coherus (CHRS) announced workforce reductions. Pfizer (PFE) and Blackstone agreed to co-fund an obesity drug. Key stock prices were reported.

$NVCRHighAI 9/10

NovoCure Receives FDA Not Approvable Letter for Optune Mya Application

NovoCure received an FDA Not Approvable Letter for its Optune Mya application to treat brain metastases from non-small cell lung cancer. The FDA cited uncertainty about clinical benefit, but raised no safety concerns. NovoCure is evaluating the feedback and exploring potential paths to approval without additional studies, though future submissions may not lead to approval.

$NVCRMedAI 8/10Clinical / regulatory

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer BAAR, Switzerland—November 9, 2026-- Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Lett

Related tickers